Why psoriatic arthritis trial monitoring matters in 2026
Psoriatic arthritis (PsA) is one of the most commercially competitive immune-mediated inflammatory disease (IMID) indications. The therapeutic landscape spans TNF inhibitors, IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), IL-23 inhibitors (guselkumab, risankizumab), JAK inhibitors (upadacitinib, tofacitinib), and the oral TYK2 inhibitor deucravacitinib. Each approved agent competes for the same patient population across diverse disease manifestations — joint disease, skin disease, dactylitis, enthesitis, and axial involvement.
The competitive intensity in PsA means professionals tracking this market need daily awareness of new clinical programs. A new IL-17/IL-23 dual-targeting biologic or a novel oral mechanism entering Phase 2 can reshape BD valuations and strategic planning.
Key signals in the PsA pipeline in 2026:
- Next-generation IL-17 programs: IL-17A/F dual blockers, improved dosing regimens, biosimilar market entry
- IL-23 inhibitor combinations and head-to-head comparative trials against JAK inhibitors
- TYK2 inhibitors beyond deucravacitinib — next-generation oral agents with improved selectivity
- Novel oral mechanisms: sphingosine-1-phosphate modulators, PDE4 inhibitors in new formulations
- Axial PsA programs: clinical trials specifically addressing the spondyloarthritis manifestation
- Biomarker-stratified trials using imaging (ultrasound, MRI) and inflammatory markers
- Biosimilar programs for approved biologics entering late-stage development
Get daily psoriatic arthritis trial digest
Set your profile once. Receive a filtered daily digest of new and updated PsA trials. free plan.
Get the Free DigestWhat DataLookout monitors for psoriatic arthritis
Configure your profile with condition and mechanism keywords as specific or broad as needed:
- Condition keywords: "psoriatic arthritis", "PsA", "spondyloarthritis", "axial PsA", "psoriatic spondyloarthritis"
- Mechanism keywords: "IL-17 inhibitor", "IL-23 inhibitor", "JAK inhibitor", "TYK2 inhibitor", "TNF inhibitor", "PDE4 inhibitor"
- Target-specific: "IL-17A", "IL-17F", "IL-23 p19", "JAK1", "JAK3", "TYK2", "ustekinumab", "secukinumab", "ixekizumab"
- Phase filter: Phase 2/3 for competitive intelligence, or all phases for complete pipeline visibility
- Sponsor filter: Industry-sponsored programs for BD and competitive tracking
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Psoriatic Arthritis trial on your watchlist. Each change is classified as critical, notable, or minor, so a trial quietly adding a dozen new sites does not read the same as a contact-details edit.
Who uses psoriatic arthritis trial monitoring
Immunology pharma BD and competitive intelligence teams
Companies with assets in PsA — or evaluating entry into the IMID space — track new trial registrations to assess competitive dynamics. With multiple approved mechanisms competing across the same patient population, understanding where competitors are investing in next-generation approaches, combination strategies, or head-to-head comparisons shapes in-licensing priorities and clinical development strategy.
Rheumatology-focused biotech analysts
Investors covering inflammatory disease use trial registrations to track pipeline developments before they become widely reported. A new Phase 3 TYK2 program in PsA or a head-to-head trial between IL-17 and IL-23 inhibitors signals competitive positioning that affects valuation across the IMID landscape.
Rheumatology medical affairs and key opinion leader engagement teams
Medical affairs professionals at companies with PsA products track competitor programs to anticipate label changes, prepare for new competitive entries in the market, and inform key opinion leader engagement priorities as new data emerges.
Psoriasis and psoriatic arthritis patient organizations
Patient advocacy organizations track the PsA pipeline to connect patients with inadequate response to current therapies with appropriate clinical trial opportunities — particularly patients with challenging disease manifestations like dactylitis, enthesitis, or axial involvement.
Frequently asked questions
How current is the psoriatic arthritis trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated as sponsors register new trials or submit protocol amendments.
Can I monitor PsA and plaque psoriasis trials together?
Yes. Many biologics approved for psoriatic arthritis were first developed for plaque psoriasis — you can configure a combined profile tracking both conditions, or separate profiles if your intelligence needs are distinct.
Does DataLookout cover axial spondyloarthritis trials separately?
Yes. Adding keywords like "axial spondyloarthritis", "ankylosing spondylitis", or "nr-axSpA" will surface trials in the broader spondyloarthritis category, often relevant to the same mechanism of action programs active in PsA.
Does DataLookout include biosimilar trials for PsA biologics?
Yes — biosimilar Phase 3 programs registered on ClinicalTrials.gov are included and will appear when the reference biologic name (e.g., "adalimumab", "secukinumab") appears in the trial record.
155 active trials, 87 recruiting.
Industry sponsors run 59 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 27.
| Top industry sponsor | Active trials |
|---|---|
| Johnson & Johnson / Janssen | 12 |
| AbbVie | 5 |
| Bristol-Myers Squibb | 4 |
| Novartis Pharmaceuticals | 4 |
| UCB Biopharma SRL | 4 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| WORK-ON Vocational Rehabilitation for People With Inflammatory Arthritis NCT06299917 | Active, Not Recruiting | Completion pushed: 2027-09-01 → 2028-08-01 | 2026-09-16 |
| A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With… NCT04908189 | Active, Not Recruiting | Primary completion pushed: 2024-02-06 → 2024-11-07 | 2026-09-12 |
| Cytokine Expression in Psoriasis Patients With and Without Joint Involvement NCT05307809 | Recruiting | Completion pushed: 2026-08-18 → 2027-02-18 | 2026-09-01 |
| A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants… NCT04929210 | Active, Not Recruiting | Primary completion pushed: 2026-08-04 → 2027-04-01 | 2026-08-29 |
| INSELMA - a Randomised Controlled Trial NCT06583980 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-09-12 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.